ALYMSYS
PeakmAbbevacizumab-maly
BLAINJECTIONINJECTABLE
Approved
Apr 2022
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
4/8 — Partial
ALYMSYS (bevacizumab-maly) is vascular endothelial growth factor-directed antibody interactions [moa]. First approved in 2022.
Drug data last refreshed 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALYMSYS (bevacizumab-maly) is a monoclonal antibody that inhibits Vascular Endothelial Growth Factor (VEGF), blocking tumor angiogenesis and starving cancers of blood supply. It is approved across 19 indications spanning solid tumors (colorectal, breast, ovarian, lung, pancreatic cancers) and one ophthalmologic indication (age-related macular degeneration). The drug works by binding VEGF and preventing its interaction with endothelial growth factor receptors on blood vessel cells.
$0.486MPart D
PeakALYMSYS is in peak commercial lifecycle with low Part D penetration, indicating early market establishment and potential for team expansion in commercial and medical affairs roles.
Mechanism of Action
Vascular Endothelial Growth Factor-directed Antibody Interactions
Pharmacologic Class:
Vascular Endothelial Growth Factor Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ALYMSYS shows zero linked job postings at the time of analysis, indicating minimal active hiring or a consolidated team structure. Career opportunities are likely concentrated in established brand management, medical affairs, and clinical operations roles supporting the mature product.
External Resources
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.